CRISPR THERAPEUTICS AG Reports Earnings Results for Q2 2023
August 27, 2023
🌥️Earnings Overview
For the second quarter of fiscal year 2023, CRISPR THERAPEUTICS AG ($NASDAQ:CRSP) reported total revenue of USD 70.0 million, a whopping increase from the 0.2 million reported in the same period for the prior year. However, net income for the quarter was USD -77.7 million, a decrease from the -185.8 million reported in the same period of the previous year.
Share Price
On Monday, CRISPR THERAPEUTICS AG reported its earnings results for the second quarter of 2023. The stock opened at $50.8 and closed at $48.3, a drop of 5.1% from the prior closing price of 51.0. This drop was likely due to the company’s financial results not meeting expectations. The stock price drop reflects this sentiment and could affect the company’s performance in the coming quarters. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for CRSP. More…
| Total Revenues | Net Income | Net Margin |
| 170.1 | -415.93 | -244.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for CRSP. More…
| Operations | Investing | Financing |
| -342.99 | 246.68 | 39.76 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for CRSP. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 2.2k | 380.99 | 22.88 |
Key Ratios Snapshot
Some of the financial key ratios for CRSP are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -16.2% | – | -278.4% |
| FCF Margin | ROE | ROA |
| -212.7% | -16.1% | -13.5% |
Analysis
At GoodWhale, we analyze the fundamentals of CRISPR THERAPEUTICS AG in order to give investors a better understanding of the company. Our Star Chart shows that CRISPR THERAPEUTICS AG is strong in asset, growth, and profitability, but weak in dividend. The company is classified as ‘rhino’, a type of company we conclude that has achieved moderate revenue or earnings growth. Considering CRISPR THERAPEUTICS AG’s cashflows and debt, the company has an intermediate health score of 6/10, indicating that it may be able to pay off debt and fund future operations. This makes CRISPR THERAPEUTICS AG an attractive option for investors looking for moderate growth opportunities. Furthermore, with its strong fundamentals and moderate growth prospects, the company could also appeal to those who are looking for stable investments. More…
Peers
Its competitors are Vertex Pharmaceuticals Inc, Intellia Therapeutics Inc, and Editas Medicine Inc.
– Vertex Pharmaceuticals Inc ($NASDAQ:VRTX)
Vertex Pharmaceuticals Inc is a biotechnology company that focuses on the development and commercialization of small molecule drugs for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Vertex Pharmaceuticals Inc has a market cap of 77.84B as of 2022 and a return on equity of 21.39%. The company focuses on the development and commercialization of small molecule drugs for the treatment of serious diseases.
– Intellia Therapeutics Inc ($NASDAQ:NTLA)
Intellia Therapeutics Inc is a biopharmaceutical company that uses genome editing to develop cures for serious diseases. The company has a market cap of 4.32B as of 2022 and a return on equity of -31.41%. Intellia’s mission is to develop curative genomic medicines for serious diseases using a proprietary technology platform, which includes CRISPR/Cas9.
– Editas Medicine Inc ($NASDAQ:EDIT)
Editas Medicine Inc is a genomic editing company. Its mission is to translate the power and potential of the CRISPR/Cas9 and CRISPR/Cas13a (also known as Cpf1) systems into a robust pipeline of medicines for people living with serious and life-threatening diseases. The company has a market cap of 908.36M as of 2022 and a Return on Equity of -28.99%.
Summary
CRISPR Therapeutics AG reported total revenue of USD 70.0 million and net income of USD -77.7 million for the second quarter of fiscal year 2023, ending June 30, 2023. This is a significant increase in revenue from the 0.2 million reported in the same period last year, but a decrease in net income from -185.8 million. The stock price for the company moved down the same day, providing investors with an indication of potential weak performance in the future. It is important for investors to understand the company’s financial position in order to make informed decisions on whether to invest in CRISPR Therapeutics AG.
Related Posts
Recent Posts
